Updates
** Shares of drugmaker Eli Lilly LLY.N rise 12.7% to $828.67 premarket
** Company says its small molecule oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** Shares of Structure Therapeutics GPCR.O, which is also developing a small molecule oral weight loss drug, gain 17.7% before the bell
** U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 6%
** Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 5.1% and Amgen AMGN.O down 2.8%
** Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD
(Reporting by Christy Santhosh in Bengaluru)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。